Gilead Sciences 2014 Annual Report Download - page 4

BOARD OF DIRECTORS
John C. Martin, PhD
Chairman and Chief Executive Ocer,
Gilead Sciences
John F. Cogan, PhD
Lead Independent Director,
Gilead Sciences
Senior Fellow, Hoover Institution,
Stanford University
Etienne F. Davignon
Minister of State for Belgium,
Chairman, Genfina
Carla A. Hills
Chair and Chief Executive Ocer,
Hills & Company International
Consultants
Kevin E. Lofton, FACHE
Chief Executive Ocer,
Catholic Health Initiatives
John W. Madigan
Retired Chairman and
Chief Executive Ocer,
Tribune Company
Nicholas G. Moore
Retired Global Chairman,
PricewaterhouseCoopers
Richard J. Whitley, MD
Distinguished Professor,
Loeb Scholar Chair in Pediatrics,
Professor of Pediatrics, Microbiology,
Medicine, and Neurosurgery,
University of Alabama at Birmingham
Gayle Edlund Wilson
Chairman Emeritus of COSMOS,
The California State Summer School
for Math and Science
Per Wold-Olsen
Retired President, Human Health
Intercontinental Division,
Merck & Co., Inc.
DIRECTOR EMERITUS, GILEAD
SCIENCES BOARD OF DIRECTORS
George P. Shultz, PhD
Distinguished Fellow,
Hoover Institution,
Stanford University
SENIOR LEADERSHIP TEAM
John C. Martin, PhD
Chairman and Chief Executive Ocer
John F. Milligan, PhD
President and Chief Operating Ocer
Norbert W. Bischoerger, PhD
Executive Vice President,
Research and Development and
Chief Scientific Ocer
Robin L. Washington
Executive Vice President and
Chief Financial Ocer
Gregg H. Alton
Executive Vice President,
Corporate and Medical Aairs
Paul R. Carter
Executive Vice President,
Commercial Operations
Andrew Cheng, MD, PhD
Executive Vice President,
HIV Therapeutics and Development
Operations
John McHutchison, MD
Executive Vice President,
Clinical Research
Taiyin Yang, PhD
Executive Vice President,
Pharmaceutical Development and
Manufacturing
Katie L. Watson
Senior Vice President,
Human Resources
SCIENTIFIC ADVISORY BOARD
Joel R. Hu, PhD (Chairperson)
Retired Vice President of
Medicinal Chemistry,
Merck Research Laboratories
Kenneth C. Anderson, M.D.
Kraft Family Professor of Medicine,
Harvard Medical School
Director, LeBow Institute for Myeloma
Therapeutics
Director, Jerome Lipper Multiple
Myeloma Center
Dana-Farber Cancer Institute
Paul Berg, PhD
Cahill Professor of
Biochemistry, Emeritus,
Stanford University School of Medicine
Francis V. Chisari, MD
Professorand Head
Division of Experimental Virology
Department of Immunology and
Microbial Science
The Scripps Research Institute
Brian J. Druker, MD
Director, Knight Cancer Institute
Associate Dean for Oncology, School
of Medicine
JELD-WEN Chair of Leukemia
Research
Oregon Health & Science University
Investigator, Howard Hughes Medical
Institute
Mark C. Genovese, MD
James W. Raitt Endowed Professor
of Medicine
Co-Division Chief, Division of
Immunology and Rheumatology
Stanford University School of Medicine
Robert A. Harrington, MD
Arthur L. Bloomfield Professor of
Medicine, Chair, Department of
Medicine, Stanford University
School of Medicine
Paul E. Klotman, MD
President, Chief Executive Ocer, and
Executive Dean
John E. and Clara B. Whitmore
Professor, Baylor College of Medicine
Malcolm MacCoss, PhD, FRSC
Founder and Member, Bohicket
Pharma Consulting LLC
Visiting Professor of Chemistry for
Medicine, University of Oxford, UK
Ex-Vice President of Drug Discovery
Sciences, Merck Research
Laboratories, Rahway, NJ
Ex-Group Vice President of Chemistry,
Schering-Plough Research Institute
John W. Mellors, MD
Professor of Medicine,
Chief, Division of Infectious Diseases,
University of Pittsburgh School
of Medicine
Eugene R. Schi, MD
Leonard Miller Professor of Medicine
Dr. Nasser Ibrahim Al-Rashid Chair in
the Schi Center for Liver Diseases
Director, Schi Center for Liver
Diseases
Director, Hepatology Research
Laboratory
University of Miami Miller School of
Medicine
Robert T. Schooley, MD
Professor of Medicine and Head,
Division of Infectious Diseases,
Vice Chair of Department of Medicine,
University of California, San Diego
Eric J. Topol, MD
Director, Scripps Translational
Science Institute
Chief Academic Ocer,
Scripps Health
Professor of Genomics,
The Scripps Research Institute
CORPORATE SECRETARY
Gregg H. Alton
Executive Vice President,
Corporate and Medical Aairs
INDEPENDENT REGISTERED
PUBLIC ACCOUNTANTS
Ernst & Young, LLP
Redwood City, California
CORPORATE HEADQUARTERS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404 USA
[phone] or [phone]
www.gilead.com
STOCKHOLDER INQUIRIES
Inquiries from our stockholders and
potential investors regarding our
company are always welcome and will
receive a prompt response. Please
direct your requests for information to:
Investor Relations
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404 USA
[phone] or [phone]
Information regarding Gilead is also
available at www.gilead.com.
STOCK LISTING
Gilead common stock is traded on the
Nasdaq Global Select Stock Market,
under the symbol GILD.
ANNUAL MEETING
The annual meeting of stockholders
will be held at 10:00 a.m. on
Wednesday, May 6, 2015, at the Westin
San Francisco Airport Hotel.
TRANSFER AGENT AND REGISTRAR
Communications concerning stock
transfer requirements, lost certificates
and changes of address should be
directed to the Transfer Agent:
Computershare
P.O. BOX 30170
College Station, TX 77842-3170
[phone]
www.computershare.com/investor
EQUAL OPPORTUNITY EMPLOYER
Gilead Sciences is proud to be an
equal opportunity employer and
extends employment to men and
women from culturally diverse
backgrounds. Our environment
respects individual dierences and
recognizes each employee as an
integral member of our company.
Our workforce reflects these values
and celebrates the individuals who
make up our growing team.
CORPORATE INFORMATION
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of patients suff ering from life-threatening diseases worldwide.
Gilead has operations in more than 30 countries worldwide, with headquarters inFoster City, California.
AmBisome, Cayston, Complera, Emtriva, Eviplera, Gilead, Gilead Sciences, the Gilead logo design, Harvoni, Hepsera, Letairis,
Ranexa, Sovaldi, Stribild, Truvada, Tybost, Viread, Vistide, Vitekta, Volibris and Zydelig are registered trademarks of Gilead Sciences,
Inc. or one of its related companies. Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. Lexiscan is
a registered trademark of Astellas U.S. LLC. Tamifl u is a registered trademark of Hoff mann-La Roche Inc. Macugen is a registered
trademark of EyeTech, Inc.
Full U.S. prescribing information for Gilead products is available at www.gilead.com.
4